iBio, Inc. (IBIO) Arranges Production of IBIO-CFB03 With Caliber Biotherapeutics

April 27, 2015 8:34 AM EDT

iBio, Inc. (NYSE: IBIO), has engaged Caliber Biotherapeutics LLC to scale-up and produce materials for clinical development of the first of iBio's proprietary anti-fibrosis products, IBIO-CFB03. Caliber's production will be used for IND-enabling toxicology studies and initial human clinical trials of IBIO-CFB03.

iBio is the exclusive worldwide licensee of the patents developed by Dr. Carol Feghali-Bostwick for therapies against fibrotic diseases. Dr. Feghali-Bostwick, the inventor of IBIO-CFB03, is collaborating with iBio for the development of various applications of her invention to address systemic sclerosis, idiopathic pulmonary fibrosis, and scleroderma. She is the Kitty Trask Holt Endowed Chair and Professor of Medicine in the Division of Rheumatology and Immunology at the Medical University of South Carolina where iBio expects the first human clinical trials of IBIO-CFB03 to be conducted.

The expansion in 2014 of iBio's exclusive technology collaboration with Novici Biotech LLC broadened iBio's fibrosis therapeutics program through a combination of the strengths of iBio's proprietary iBioLaunch" platform technology with Novici's patented optimization technology. iBio then engaged CBR International Corporation for strategic regulatory and clinical services and assembled a Clinical Advisory Board of internationally recognized experts in fibrotic diseases to assist the company in clinical product development and human trial design.

"Our engagement of Caliber, which has pilot and full-scale production capabilities, enables us to satisfy all of our production needs for human clinical trials of IBIO-CFB03," said Robert Erwin, iBio's President.

Caliber, located in College Station, Texas, operates the world's largest plant-made pharmaceutical protein manufacturing facility. Caliber's facilities and operations have been supported by the Cancer Prevention and Research Institution of Texas (CPRIT), U.S. Defense Advanced Research Projects Agency (DARPA) and several Texas based life sciences investors. Caliber is a licensee of iBioLaunch technology for research purposes and for commercial development of other product candidates. iBio also granted Caliber a license to iBioLaunch technology for the production of antibodies that target the Ebola virus, and is currently engaged in a collaboration with Caliber and Novici for the optimization of undisclosed biotherapeutics.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Management Comments, Momentum Movers